Diaz-Montero, C.M., S.A. El Naggar, R. El-Naggar, A.A. Khami, A.J. Montero, D.J. Cole and M.L. Salem, 2008. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8⁺CD62L^hi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol. Immunother., 57: 563-572.
CrossRef  |  

El-Naggar, S.A., 2011. Lack of the beneficial effects of mirazid (Commiphora molmol) when administered with chemotherapeutic agents on ehrlich ascetic carcinoma bearing mice. Adv. Biol. Res., 5: 193-199.
Direct Link  |  

El-Naggar, S.A., A.A. El-Brabary, M.A. Mansour, F. Abdel-Shafy and S. Talat, 2011. Anti-tumor activity of some 1,3,4-thiadiazoles and 1,2,4-triazine derivatives against ehrlichs ascites carcinoma. Int. J. Cancer Res., 7: 278-288.
CrossRef  |  Direct Link  |  

El-Naggar, S.A., I.M. Al-Sharkawi and G.A. Madkour, 2011. Susceptibility of some wild rodents widely distributed in Egyptian Foci to Schistosoma mansoni infection under laboratory conditions. Int. J. Zool. Res., 7: 358-368.
CrossRef  |  

Salem, M.L., A.A. Al-Khami, S.A. El-Naggar, C.M. Diaz-Montero and D.J. Cole, 2010. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a FLT3L-dependent expansion of dendritic cells. J. Immunol., 184: 1737-1747.
PubMed  |  

Salem, M.L., A.N. Kadima, S.A. El-Naggar, M.P. Rubinstein, Y. Chen, W.E. Gillanders and D.J. Cole, 2007. Defining the ability of Cyclophosphamide preconditioning to enhance the antigen-specific CD8+T-cell response to peptide vaccination: Creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother., 30: 40-53.
PubMed  |  

Salem, M.L., C.M. Diaz-Montero, A.A. Al-Khami and S.A. El-Naggar et al., 2009. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly (I:C). J. Immunol., 182: 2030-2040.
CrossRef  |  Direct Link  |  

Salem, M.L., C.M. Diaz-Montero, S.A. El-Naggar, Y. Chen, O. Moussa and D.J. Cole, 2008. TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naive recipient mice vaccine. Epub., 27: 549-557.
CrossRef  |  PubMed  |  Direct Link  |  

Salem, M.L., F.Q. Alenzi, N. Nath, S.A. El-Naggar and A.A., Al-Khami et al., 2009. Plasticity of T cell differentiation: A double-edged sword for immune responses. Immunol. Endocrine Metab. Agents Med. Chem. J., 9: 90-105.
CrossRef  |  

Salem, M.L., S.A. EL-Naggar, A. Kadima, W.E. Gillanders and D.J. Cole, 2006. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells and macrophages with the induction of a beneficial cytokine milieu. Vaccine, 24: 5119-5132.
CrossRef  |  Direct Link  |  

Salem, M.L., S.A. El-Naggar and D.J. Cole, 2010. Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cell. Immunol., 261: 134-143.
CrossRef  |  

Salem, M.L., W.E. Gillanders, A.N. Kadima, S. El-Naggar and M.P. Rubinstein et al., 2006. Novel non-viral delivery approaches for Interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J. Interferon. Cytokine Res., 9: 593-608.
CrossRef  |  Direct Link  |